Thomas Son

发表

Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

P. Moore, Syd Johnson, S. Burke, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Development of an Fc-Enhanced Anti – B 7-H 3 Monoclonal Antibody with Potent Antitumor Activity

P. Moore, Syd Johnson, S. Burke, 2012 .

Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer

Y. Li, P. Moore, Sharad K Sharma, 2017, Molecular Cancer Therapeutics.

Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist

U. Hacksell, D. Weiner, M. Brann, 2004, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological and behavioral profile of ACP-103, a novel 5-HT 2A receptor inverse agonist

Robert I. Davis, M. Geyer, D. Weiner, 2006 .

Abstract 1201: Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer

P. Moore, Syd Johnson, S. Koenig, 2016 .

Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator

F. Piu, R. Olsson, Thomas Son, 2008, The Journal of Steroid Biochemistry and Molecular Biology.

Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.

A. Dastur, P. Moore, T. Chittenden, 2022, Molecular cancer therapeutics.

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

K. Mcfarland, D. Bonhaus, J. Lameh, 2010, Neuropharmacology.

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Ethan S. Burstein, Fabrice Piu, Mark R. Brann, 2006, Journal of Pharmacology and Experimental Therapeutics.